On October 8, a conference call was held between our Canadian pharmacist, Colin Holyk of Kerrisdale Pharmacy, Vancouver, and MAPS’ clinical research staff. The team planned our continuing negotiations with Health Canada regarding the importation of our Canadian study’s supply of MDMA from Switzerland. We also are preparing to submit a protocol amendment to our Canadian Institutional Review Board (IRB) to make protocol changes that will align with all of our other MDMA/PTSD studies. This includes adding one-year follow-up measures and audio and video recording of the treatment sessions. This consistency is important so we can conduct a meta-analysis when all studies are complete. The audio and video recording will help us train therapists and independent raters when we move on to the large-scale multi-site studies.